

“THE PREVENTION EQUATION”

The level of Protection conferred (the number of infections averted) depends on three factors:

- ❖ Efficacy of the Method**
- ❖ Consistency of use within Partnership**
- ❖ Extent of use within a Sub-population**

A microbicide -a low-efficacy method- used with high levels of consistency would offer the same protection as a high-efficacy method- the condom-used less consistently.

A 90% efficacious method used 20% of the time prevents fewer infections than:

- 70% efficacious method used 30% of the time, or**
- 50% efficacious method used 40% of the time, or**
- 30% efficacious method used 60% of the time**

Source: Watts *et al*, 2002


Innovative Technologies for Female Condoms-Requirements and Test Methods

Dr.S.Mokkapati,Deputy Director-General
Indian Council of Medical Research
New Delhi, india

Global Consultation on the Female Condom

Radisson Plaza Lord Baltimore
September 26-29,2005

HIV-1 Infectable Cells are Concentrated in the Cervix¹



¹Healthy women without evident genital tract infection

²T-CD4: T lymphocytes, Mφ-Macrophages, LC-Langerhans Cells


■ Cervix

Cervix: Site of High Susceptibility

- Pregnancy
- Classical cervicotropic STDs (CT, GC)
- HIV
- Other cell-associated viruses
 - CMV, HTLV I, HTLV II
- Other systemic viruses
 - Hepatitis B, Hepatitis C
- Herpes and papillomaviruses


HIV-1 Coreceptor Expression in the Female Genetal Tract

B. RT-PCR



HIV-1 Coreceptor Expression in the Female Genetal Tract

CXCR-4



Comparison with other methods of contraception

Comparison of condom with other birth control procedures and safety										
Age of female	First			Second*			Third		Fourth	
	Far better	Comparable	Worse	Far better	Comparable	Worse	Far better	Comparable	Far better	Comparable
20 - 25 years	16.00	8.00	4.00	24.00	4.00	-	18.00	10.00	16.00	12.00
25 - 30 years	8.00	30.00	4.00	16.00	24.00	2.00	16.00	26.00	20.00	22.00
30 - 35 years	12.00	8.00	2.00	10.00	8.00	4.00	12.00	10.00	14.00	8.00
35 - 40 years	4.00	2.00	2.00	2.00	6.00	-	4.00	4.00	4.00	4.00
Overall	40.00	48.00	12.00	52.00	42.00	6.00	50.00	50.00	54.00	46.00

The condom was comparable and far better than other contraceptive methods.

* None of the participants found the condom worse than other methods of contraception after the second trial.

Users willing to buy the Female condom

Age of female	Purchase the product from market									
	First			Second		Third		Fourth		
	Yes	No	Can't Say	Yes	No	Yes	No	Yes	No	Can't Say
20 - 25 years	14.00	10.00	4.00	24.49	4.08	18.75	10.42	22.00	6.00	-
25 - 30 years	30.00	8.00	4.00	32.65	8.16	35.42	6.25	34.00	4.00	4.00
30 - 35 years	10.00	12.00	-	14.29	8.16	16.67	4.17	18.00	2.00	2.00
35 - 40 years	6.00	2.00	-	6.12	2.04	6.25	2.08	8.00	-	-
Overall	60.00	32.00	8.00	77.55	22.45	77.08	22.92	82.00	12.00	6.00

60% of participants were interested in buying the product from the market after first trial. This increased to 82% by the fourth trial.

Overall Pleasure Levels

Overall Pleasure level*		
Age	Female	Male
20 - 25 years	1.93	1.67
25 - 30 years	2.05	2.13
30 - 35 years	2.06	2.20
35 - 40 years	2.00	1.96
Over 40 years	-	1.67

Overall it is observed both male and female in the age group of 20-25 years find it more pleasurable than the age group 30-35 years .

Overall Pleasure level*		
Height difference	Female	Male
Male shorter	1.50	3.17
Taller upto 0.2'	1.77	1.85
Taller form 0.2' to 0.4'	2.07	2.07
Taller form 0.4' to 0.6'	2.22	2.11
Taller form 0.6' to 0.8'	2.05	2.10
Taller than 0.8'	2.04	2.08


It is also observed that when the height difference between the partners are less both male and female gets more pleasure. When the height difference is around half a feet the pleasure is minimum for both the sexes.


- 1 Very Pleasurable better than natural pleasure
- 2.5 Natural Pleasure
- 5 Pain or Irritation felt



**Female Condom use in High-Risk Women
as Predictor of Microbicide Readiness**

**Microbicide Should Inactivate Diverse Pathogens and Sperm
Yet Not Disturb Vaginal Flora or Epithelium**





Design specific standards and specifications

- Clinical testing
- Design testing

Comparative functional clinical trial

- Performance testing
- Efficacy
- Acceptability of new designs

Performance Tests

- Bursting volume
- Pressure
- Freedom for holes

Female Condom Designs

- Dimensions
- Stability
- Biocompatibility
- Visible defects
- Viral penetration

Retention Features

- Part of the design
- Designs specific tests

Web of Advocacy



Thanks!!!

